239 results about "Virus inactivation" patented technology

The invention relates to the field of biological medicines, and particularly provides a purification method of an anti-IL-11 monoclonal antibody, which comprises the following steps: affinity chromatography: preliminarily purifying and concentrating a target protein containing the anti-IL-11 monoclonal antibody, and carrying out virus inactivation on a protein product in an acid solution to obtain a protein sample; anion exchange chromatography: carrying out secondary purification on the protein sample, and collecting flow-through liquid; and cation exchange chromatography: carrying out refined purification on the flow-through liquid to obtain a protein solution of the anti-IL-11 monoclonal antibody. A proper purification process is provided for the anti-IL-11 monoclonal antibody, the purification efficiency and the recovery rate of the anti-IL-11 monoclonal antibody are improved, flow-through liquid collected by anion exchange chromatography directly enters cation exchange chromatography without treatment, sample treatment or solution replacement is not needed in the process, the purification time is saved, and the purification efficiency and the recovery rate of the anti-IL-11 monoclonal antibody are improved. Impurities are prevented from being introduced in the purification process, the purity of purified protein is improved, and high practicability is achieved.

The invention belongs to the technical field of medical treatment, and discloses a blood product virus inactivation system based on a synergistic effect of nano-catalysis photochemical inactivation and low-temperature plasma, the system comprises: a nano-photocatalysis inactivation module adopting titanium dioxide TiO2 and graphite phase carbon nitride g-C3N4 nano-materials as photocatalysts; the low-temperature plasma inactivation module adopts a low-temperature plasma generator to generate plasma cloud above the blood product and release active particles; the dynamic fluid stirring module is used for enabling the blood product to uniformly receive photocatalysis and plasma inactivation effects through a microfluid mixing technology so as to ensure the uniformity of virus inactivation; the sensing monitoring and intelligent feedback module is used for monitoring the residual quantity of viral nucleic acid and the activity of protein in the blood in real time by adopting a spectrum sensor and a biochemical sensor. The method can be widely applied to the fields of clinical blood transfusion, blood product manufacturing, blood disease treatment and the like, promotes the progress of a blood safety guarantee technology, reduces the virus infection risk and improves the patient safety.

The invention relates to the technical field of repair materials, and particularly discloses an extracellular matrix fiber material as well as a preparation method and application thereof. The invention discloses a preparation method of an extracellular matrix fiber material. The preparation method comprises the following steps: taking animal tissues, and carrying out virus inactivation, decellularization and antigen removal, degreasing, drying, grinding and sterilization; the decellularization and antigen removal method comprises the following specific steps: sequentially soaking a sample with a surfactant solution for h; then, soaking treatment is carried out by adopting a salt-alkali solution which contains 0.05-3 mol / L of salt and has the pH value of 8-11; then carrying out soaking treatment by adopting a 0.1-1wt% enzyme solution; and in degreasing, one or more of normal hexane, trichloromethane, dichloromethane, methanol, ethanol, acetone, diethyl ether and ethyl acetate are used for soaking the sample. According to the technical scheme, the ECM powder particle material with high growth factor content is prepared.

The invention belongs to the technical field of protein purification, and particularly relates to a recombinant human metapneumovirus pre-fusion F protein purification method which comprises the following steps: filtering fermentation liquor by using a deep filter to obtain fermentation clear liquor; capturing the recombinant hMPV F protein from the fermentation clarified liquid by using hydroxyapatite to obtain a purified liquid 1; carrying out virus inactivation on the purified solution 1 by adopting a low-pH method to obtain an inactivated solution; carrying out anion exchange chromatography on the inactivated solution to obtain a purified solution 2; carrying out composite weak anion chromatography on the purified solution 2 to obtain a purified solution 3; performing UF / DF on the purified liquid 3 to obtain an ultrafiltrate; and carrying out virus removal nanofiltration and sterile filtration on the ultrafiltrate to obtain a recombinant hMPV F stock solution. The method is simple and convenient, has good repeatability, is suitable for large-scale production, and can be effectively used for producing the recombinant human metapneumovirus pre-fusion F protein vaccine.

The invention discloses a method for extracting human placenta tissue and preparing human placenta tissue injection, which comprises the following steps: screening placenta, unfreezing, soaking, rinsing, draining, weighing, preparing liquid, mincing, grinding and hydrolyzing, adding acid water to adjust the pH value for acid hydrolysis, adding alkaline water to adjust the pH value for alkaline hydrolysis after hydrolysis, and then inactivating viruses. The preparation method comprises the following steps: preparing a human placenta tissue solution, carrying out virus inactivation, carrying out rough filtration and fine ultrafiltration to remove bacteria and filtration, carrying out nanofiltration virus removal treatment by using a nano-membrane to obtain a sterile human placenta tissue solution stock solution, carrying out dilution preparation on the human placenta tissue solution stock solution according to the stock solution concentration, carrying out sterile subpackaging in bottles, sealing and detecting. The prepared human placenta tissue fluid is high in biological activity, the biological activity of the human placenta tissue fluid is effectively guaranteed, and meanwhile the biological safety of the human placenta tissue fluid is guaranteed by adopting a two-time virus inactivation and removal method.

The invention discloses a preparation method of human urinary kallidinogenase for reducing bacterial endotoxin, which comprises the following steps: 1) dissolving a human urinary kallidinogenase crude product, and sequentially performing strong anion exchange column chromatography, hydrophobic column chromatography, virus inactivation and affinity column chromatography to obtain a human urinary kallidinogenase intermediate solution; (2) performing strong cation exchange column chromatography on the human urinary kallidinogenase intermediate solution obtained in the step (1), and eluting to obtain a bacterial endotoxin content of 1t and a unit titer of more than or equal to 15PNA unit / ml; and 0.16 EU / PNA unit of human urinary kallidinogenase. The human urinary kallidinogenase obtained by the preparation method has higher titer and lower bacterial endotoxin while ensuring high yield and high purity, is convenient for subsequent post-treatment and storage, and has higher safety during clinical use.

The present invention provides a method for inactivating viruses in liquid biological products. The method uses a virus inactivation device to inactivate viruses in liquid biological products. The virus inactivation device includes a feeding part, a centrifugation part, and a discharging part. The centrifugation part is provided with an ultraviolet lamp. The liquid biological products are continuously fed into the centrifugation part through the feeding part. Under the action of centrifugation, the liquid biological products are thinned to a liquid layer thickness of 0.01 cm to 0.2 cm, and at the same time, the viruses are inactivated by ultraviolet irradiation through the ultraviolet lamp. After the viruses are inactivated, the liquid biological products are continuously discharged from the centrifugation part to the discharging part under the action of centrifugation, and are discharged from the virus inactivation device through the discharging part. The retention time of the liquid biological products in the centrifugation part is controlled to be 5 to 60 s, the irradiation intensity of the ultraviolet lamp is 500 to 10,000 μW / cm<supgt;2< / supgt;, and the irradiation wavelength of the ultraviolet lamp is 254 to 280 nm. The present invention is a continuous method for inactivating viruses in liquid biological products.

A continuous flow reactor having a plurality of interwoven flow paths in fluid communication to form a single continuous flow reactor tube having a single flow path.

The invention discloses a freeze-dried human rabies vaccine and a preparation method thereof, and belongs to the technical field of viral vaccines. The method comprises the following steps: (1) cell culture; (2) virus inoculation; (3) harvesting viruses; (4) concentration and purification: clarifying the harvested virus liquid through a filter, carrying out ultrafiltration concentration through an ultrafiltration membrane to obtain a concentrated solution, and purifying by adopting a column chromatography to obtain a chromatographic solution; (5) preparing a stock solution: inactivating and hydrolyzing the chromatographic solution to obtain a virus inactivation solution, and adding human serum albumin into the virus inactivation solution to obtain the stock solution; (6) preparing a semi-finished product: diluting with a stabilizer to prepare the semi-finished product, wherein the stabilizer comprises the following raw materials: human serum albumin, araboxylan, L-arginine hydrochloride, casein phosphopeptides, alpha-tocopherol nicotinate, a solvent and the like; and (7) preparing a finished product. The rabies vaccine disclosed by the invention is excellent in quality and stable in immune efficacy, and liquid is clear after redissolution.

The invention belongs to the technical field of rabies vaccines, and particularly relates to a purification method of a rabies virus inactivated vaccine, which comprises the following steps: step 1, carrying out passage by using a Walvax-2 cell strain through a cell factory method, and carrying out multiplication culture on the passage production cells in a microcarrier bioreactor; 2, cleaning the cells with a treating fluid, inoculating the cells with a rabies virus fixed strain, and preparing and culturing a rabies virus solution; step 3, carrying out ultrafiltration concentration on the rabies virus stock solution; step 4, purifying the rabies virus concentrated solution; step 5, inactivating the rabies virus; and 6, hydrolyzing to obtain the rabies vaccine stock solution. By adopting the composite Capto Core 700 column chromatography, impure proteins can be effectively removed, the recovery rate is high, the quality of the rabies vaccine obtained by adopting a mode of firstly purifying and then adopting beta-propiolactone inactivation is excellent, and the effect of the finally obtained human diploid cell rabies vaccine stock solution is good.

Provided herein are methods of treating a fluid comprising a recombinant therapeutic protein, the method comprising the use of a biological treatment system comprising integrated unit operations including cell removal, cell retention, chromatography, viral inactivation, viral filtration, TFF, and formulation. Biological treatment systems comprising these unit operations are also provided.

The invention relates to a preparation method and application of a human immune globulin preparation stock solution, the preparation method comprises the steps of pretreatment of an initial raw material, ultrafiltration concentration and dialysis, and virus inactivation and filtration, the ultrafiltration concentration and dialysis process is completed under the participation of a dialysis buffer solution composed of a main functional component L-proline, and the human immune globulin preparation stock solution is obtained. The L-proline is used for effectively protecting human immune globulin in the preparation process of the human immune globulin preparation stock solution and the preparation, so that the influence of various unstable factors possibly causing polymerization of the human immune globulin product in the preparation process of the human immune globulin product in the prior art is effectively overcome; therefore, the stability and the quality of the human immune globulin preparation stock solution and the prepared product are effectively improved, and compared with the prior art, the technical scheme provided by the invention is simple, convenient and practical, and can achieve an extremely good technical effect, so that the human immune globulin preparation has outstanding beneficial effects and remarkable progress, and has extremely high popularization and application values.

The invention relates to the field of ultraviolet sterilization systems, in particular to an integrated ultraviolet sterilization system utilizing a UVC deep ultraviolet chip, which comprises a UVC deep ultraviolet chip lamp bead module serving as a core light source to emit deep ultraviolet light for sterilization; the self-adaptive heat dissipation module is attached to the UVC deep ultraviolet chip lamp bead module through heat conduction silicone grease and used for dynamically guiding out heat of the UVC deep ultraviolet chip lamp bead module; and the optical power closed-loop driving module is electrically connected with the UVC deep ultraviolet chip lamp bead module and is used for outputting stable current and performing feedback regulation according to optical power. According to the integrated ultraviolet sterilization system using the UVC deep ultraviolet chip, the high efficiency is remarkably improved: the NPSS + superlattice insertion layer enables the electro-optical conversion efficiency to be improved to more than 8%, and the deep ultraviolet light of 265-275 nm is 1t; the inactivation rate of escherichia coli and influenza viruses within 1 minute reaches 99.99%, and the disinfection and killing efficiency is improved by 30% compared with that of existing equipment.

The present invention discloses a preparation method of an active injectable gel that can withstand irradiation sterilization. The active injectable gel is composed of a collagen gel extracted from an animal source, acellular dermal matrix microparticles, bacterial cellulose, glycerol, and amino acids compounded in a certain proportion, and serves as a filling material that plays an exogenous filling and endogenous collagen regeneration role. Through the protection of glycerol and amino acids and the method of cryopackaging with liquid nitrogen or dry ice, the collagen gel can still maintain its activity and gel properties after being sterilized by Co60 irradiation, and achieve the effects of sterility and virus inactivation. By adding acellular dermal matrix microparticles and bacterial cellulose, the injection force is increased and the action time of the pure collagen gel is effectively extended to achieve a long-term effect.

The invention belongs to the field of protein purification, and relates to a method for preparing bevacizumab, which comprises the steps of affinity chromatography, virus inactivation, deep filtration, composite anion exchange chromatography, cation exchange chromatography and the like.

The invention relates to a method for inactivating viruses in a fluid, in which a starting fluid (AF) laden with an active virus is mixed in a first mixing device (2) with a virus inactivation reagent (R1) to form a reactive fluid (F) and the active virus is inactivated by incubating the reactive fluid (F), and stopping the inactivation of the virus in the reactive fluid (F) by mixing the reactive fluid (F) with another reagent (R2) or by removing the virus inactivation reagent (R1) from the reactive fluid (F), thereby producing the resulting fluid (RF). It is proposed that the active virus is inactivated by incubating a reactive fluid (F) in a container device (3) different from the first mixing device (2) and comprising a plurality of separate containers (4), the reactive fluid (F) being guided from the first mixing device (2) to the container device (3) before incubation.

The application discloses a kind of enveloped virus inactivation preparation based on medium-chain triglyceride and application thereof, the present application relates to the technical field of biological medicine external preparation, including active ingredient and auxiliary material: the active ingredient includes: high-purity medium-chain triglyceride (MCT), preferably octanoic acid (C8) and capric acid (C10) triglyceride mixture, purity ≥99%; The auxiliary material includes: food-grade antioxidant, for preventing oxidation of preparation, the content of food-grade antioxidant is 0.01-0.05%w / w, with medium-chain triglyceride as active ingredient, through the physical and chemical synergistic effect, enveloped virus is efficiently killed, for treating stubborn skin mucosa infection diseases (such as stubborn flat warts, herpes labialis, genital herpes, etc.) caused by human papillomavirus (HPV), herpes simplex virus (HSV-1 / HSV-2), varicella-zoster virus and other enveloped viruses.

Embodiments of the present disclosure describe a system and method for controlling the pH of a polypeptide-containing mixture. The pH may be controlled for any suitable purpose, for example, to inactivate a virus in the mixture. The method may include the step of eluting a mixture (e.g., an eluent) having a pH greater than, for example, 3.9 and, for example, less than, 8.5 from a chromatography column. The method may further include one or more of the steps of measuring the protein concentration of the mixture and measuring the pH of the mixture. Subsequently, the amount of acid required to reduce the pH of the mixture to a target pH may be calculated based on the protein concentration of the mixture, the pH of the mixture, or both. After calculating the amount of acid to be added, a portion of the acid may be added to the mixture, wherein said portion of the acid is sufficient to achieve the target pH.

The application relates to a double-metal hydroxide, in particular to application of a CuAl double-metal hydroxide, in particular to application of the CuAl double-metal hydroxide in preparation of a preparation for inactivation of pathogenic bacteria, fungi and viruses. The CuAl double-metal hydroxide is prepared by a formamide liquid phase stripping method. Compared with the prior art, the application solves the problem of high cost of a silver ion loaded layered double-metal hydroxide in the prior art, and realizes preparation of a low-cost, high-performance and green antibacterial material with a bactericidal and antiviral effect.

The invention relates to a cherry valley duck PLV virus vaccine as well as a preparation method and application thereof, and belongs to the technical field of virus immunity. The vaccine is prepared by taking a Parry's Lagon virus (PLV) virus strain PLV-20155 as an immunogen, the strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.46296. The invention further discloses a preparation method of the vaccine. The vaccine is a PLV-20155 virus inactivated vaccine, and the preparation method of the vaccine comprises the following steps: inoculating the PLV-20155 virus into an SPF chick embryo for propagation, harvesting a virus liquid, inactivating with formaldehyde, verifying safety, emulsifying with white oil to prepare the vaccine and the like. In addition, the vaccine disclosed by the invention can be used for effectively preventing diseases such as laying rate reduction, follicle necrosis and fallopian tube atrophy of the cherry valley ducks caused by the PLV-20155 virus, and the economic benefit of breeding is remarkably improved.

The present invention relates to the field of biomedicine, and more particularly to a method for purifying an inactivated rabies virus vaccine. The method comprises the following steps: preparing an inactivated rabies virus ultrafiltration concentrate: purifying the inactivated rabies virus ultrafiltration concentrate by chromatography; the chromatography purification specifically comprises the following steps: column cleaning: loading a composite filler into a chromatography column, connecting an AKTA to the chromatography column, cleaning, sterilizing, and setting aside; chromatography operation: equilibrating the chromatography column with PBS buffer; sample loading: loading the inactivated rabies virus ultrafiltration concentrate into the chromatography column, eluting with an eluent, and collecting the eluate corresponding to the absorption peak at an ultraviolet wavelength of 280 nm, which is the purified inactivated rabies virus vaccine; column cleaning; and results showing that the residual protein content is as low as 5.0 ng / ml, the antigen content can reach above 16.0 IU / ml, the host protein removal rate can reach above 99%, and the antigen content recovery rate can reach above 86%.

The invention discloses a method for preparing high-purity canine serum albumin, which relates to the technical field of blood products. The specific preparation method is as follows: S1, using healthy canine serum or plasma as raw material, centrifuging, and collecting supernatant; S2, using an anion exchange chromatography column to perform chromatographic separation on the supernatant, and then using the S / D method in contact with an S / D reagent to perform virus inactivation treatment on the supernatant; S3, ultrafiltration and liquid exchange on the inactivated supernatant, and then cation exchange chromatography. The method for preparing high-purity canine serum albumin uses the supernatant after centrifugal separation of canine plasma as raw material for chromatographic treatment. Compared with the traditional low-temperature ethanol precipitation process, the separation steps of low-temperature ethanol precipitation, deep filtration, and precipitation dissolution of subsequent components are reduced, the process time is shortened, and the loss of canine serum albumin is reduced, and the purity, activity, and yield of canine serum albumin are greatly improved.

The application discloses a preparation method of a tetravalent influenza virus split vaccine and belongs to the technical field of vaccines. The preparation method of the tetravalent influenza virus split vaccine comprises the following steps: pre-incubation of a chicken embryo, pre-embryo inspection, virus inoculation and culture, post-embryo inspection, cold embryo, virus harvesting, ultrafiltration clarification, zone centrifugation, desugaring, chromatography, virus splitting, virus inactivation, ultrafiltration liquid replacement, sterilization filtration and preparation of a tetravalent influenza virus split vaccine product. Compared with the prior art, the technical means adopted in the application effectively reduces the content of free formaldehyde and improves the antibody level of the vaccine.

The utility model discloses a frost prevention and dust removal device and heat exchange system based on plasma wind, including a plurality of plasma wind generation modules, the plurality of plasma wind generation modules are arranged in array, each plasma wind generation module includes an ionization unit and a high voltage conversion unit, the high voltage conversion unit is connected with a power supply, and the ionization unit is connected with the power supply. The high-voltage conversion unit is used for converting power supply voltage into high-voltage electricity needed by ionization, the ionization unit is connected with the high-voltage conversion unit, the high-voltage electricity generated by the high-voltage conversion unit is applied to the ionization unit to form a high-voltage electric field, gas molecules in air are ionized to form plasma wind, water molecule frosting can be restrained, a formed frost layer is decomposed, and the air quality is improved. Reverse circulation of the heat exchange system is not needed, the heating or refrigerating stability is improved, the service life of a compressor, a valve and other key components is prolonged, in addition, plasma air can further conduct dust removal, organic pollutant decomposition, sterilization and virus inactivation on the surface of the evaporator, the heat exchange efficiency can be improved, the operation and maintenance cost can be reduced, and the application range of the heat exchange system can be expanded.

The invention provides a method for predicting the ultraviolet inactivation effect of viruses in a liquid biological product. The method comprises the following steps: (1) detecting the absorbance value of a to-be-detected liquid biological product at a preset wavelength; (2) constructing a relation curve of the ultraviolet dose of the BSA / virus mixed solution and the decline degree of the virus titer; (3) constructing a relation curve of the ultraviolet dose of the SMZ working solution and the SMZ degradation degree; (4) constructing a relation curve of the operation parameters and the SMZ degradability; and (5) substituting preset operation parameters into the relation curve of the operation parameters and the SMZ degradability, substituting the obtained result into the relation curve of the ultraviolet dose and the SMZ degradability, substituting the obtained result into the relation curve of the ultraviolet dose and the decline of the indication virus titer, and judging the ultraviolet inactivation effect of the virus according to a predicted value of the decline of the indication virus titer. The method is accurate in prediction result, does not need to consume liquid biological products, and can be used for various virus inactivation effects under the condition that the ultraviolet dose cannot be accurately calculated.

This application provides a cell encapsulation stromal material and its manufacturing method and application. The material is prepared by cutting, low-temperature microparticulation grinding, enzymatic decomposition, cell component removal, virus inactivation, freeze-drying and radiation sterilization using cartilage from mammals such as pigs, cows, sheep, horses and deer. The method is not for diagnostic purposes, and the stromal material is used for 3D bioprinting alone or with encapsulated cells. The main components of the material are type II collagen, chondroitin sulfate and hyaluronic acid, and have the advantages of no crosslinking toxicity, low immunogenicity, good biocompatibility and can be used for human implantation. In terms of structure, it has a good surface topology structure, provides a tissue microenvironment similar to that in the body for in vitro cell culture, and can be used as a microcarrier for cell culture, as well as promote the formation of cell mass, and can encapsulate cells in the gel-state stromal during the process of cell storage and transportation, protect cells from the effects of adverse environments and improve the viability of cells.

The invention relates to an application of a cerium oxide nano-material in a vaccine adjuvant and / or a vaccine inactivator, in particular to a vaccine, when the cerium oxide nano-material is the vaccine adjuvant, the vaccine comprises the vaccine adjuvant and an immunogen; or when the cerium oxide nano material is a vaccine inactivating agent, the vaccine is a composite vaccine, the composite vaccine comprises the vaccine inactivating agent and a virus, and the virus is embedded in the cerium oxide nano material; the preparation method of the composite vaccine comprises the step of mineralizing and inactivating viruses by using a vaccine inactivator, wherein the vaccine inactivator is cerium salt. The cerium oxide can be used as a vaccine adjuvant and also can be used as a virus inactivator. The maturation of dendritic cells and macrophages can be promoted by means of regulating the level of active oxygen in immune cells and the like, and the antigen presentation efficiency is improved, so that the vaccine-induced body fluid and cellular immune response is enhanced; meanwhile, cerium salt can directly act on virus surface protein for mineralization, efficient and safe virus inactivation is achieved, and preparation of inactivated vaccines is facilitated.

The invention provides a biological product virus inactivation device and application thereof.The biological product virus inactivation device comprises an outer cylinder support, an outer cylinder, an inner cylinder, a collecting bin, an ultraviolet lamp and a driving device, the outer cylinder is arranged on the outer cylinder support and is of a hollow structure with the two ends open, and the axis of the outer cylinder is obliquely arranged relative to the horizontal plane; the inner cylinder is rotatably arranged in the outer cylinder around the axis of the inner cylinder, the inner cylinder is of a hollow structure with two open ends, and the axis of the inner cylinder coincides with the axis of the outer cylinder; the opening of the collecting bin is positioned below the lower end opening of the inner cylinder; the ultraviolet lamp is a strip-shaped lamp and is fixedly arranged in the inner cylinder or between the outer wall of the inner cylinder and the inner wall of the outer cylinder; the driving device is arranged between the outer cylinder and the inner cylinder and can drive the inner cylinder to rotate around the axis of the inner cylinder. The biological product virus inactivation device is more convenient to operate, biological product feed liquid is not prone to bubbling in the virus inactivation process, the activity of a biological product can be better reserved, and the biological product virus inactivation device is suitable for large-scale industrial treatment.

The invention discloses a method for removing methemoglobin in a hemoglobin solution. The method comprises the following steps: firstly, adjusting the pH value of the hemoglobin solution to 6.5-8.5 and the ion strength to 0-3000mmol / L; deoxidizing the hemoglobin solution to obtain a deoxidized hemoglobin solution; raising the temperature of the deoxidized hemoglobin solution to a certain temperature and maintaining the temperature for a certain time; and finally, removing suspended or precipitated substances in the solution to obtain the hemoglobin solution for removing the methemoglobin. The process steps are pure physical processes, and the MetHb component can be effectively removed on the premise that new impurities or new components are not brought into an original system; the hemoglobin structure and oxygen carrying and releasing performance are not obviously influenced, the technological process is simpler than that of a chemical method, and the cost is low. In addition, the treatment process is easy to control, the content of Hb in the solution is not affected by the process, and the property is stable. The whole adopted temperature range is similar to the temperature condition of the existing biological product pasteurization virus inactivation process, and the method has the possibility of being combined with the virus inactivation process and has good application value.